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HAEMATOPOIETIC organs of rats were examined for the
presence of platelet-activating factor (PAF) and acetylhy-
drolase before and after treatment with 5-fluoro-uracil
(5-FU) (200 mg/kg) a chemotherapeutic compound with
apoptotic effects. PAF was reported in thymus, spleen and
femoral bone marrow of rats with or without 5-FU.
Although acetylhydrolase activity in organs was not
affected by 5-FU treatment, elevated levels of PAF were
observed in thymus and spleen. For the first time PAF is
reported in haematopoietic organs of rats, strengthening
in vitro data suggesting its role in the apoptotic processes
in thymus, in the modulation ofthe immune response, and
in the regulation of haematopoiesis.
Key words: 5-Fluoro-uracil, Acetylhydrolase, Platelet-activa-
ting factor, Spleen, Thymus
PAF and haematopoiesis.
I. 5-Fluoro-uracil induces PAF
production in haematopoietic
organs of rats
Y. DenizotcA and V. Praloran
Laboratoire d’Hmatologie Exprimentale,
Facult de Mdecine, 2 rue du Dr. Marcland,
87025 Limoges, France
CA Corresponding Author
Introduction
Platelet-activating factor (PAF, 1-O-alkyl-2-
acetyl-sn-glycero-3-phosphocholine) is a phospho-
lipid mediator of inflammation which is produced
from and activates a wide variety of inflammatory
ceils such as polymorphonuclear neutrophils and
monocytes. Regulating PAF levels is of importance
since elevated levels of PAF could result in
pathological effects. Removal of the acetyl moiety
of PAF abolishes its biological activity.
2 A specific
acetylhydrolase, naturally present in blood and
tissues, regulates PAF concentrations. 3’4 PAF
exhibits potent immunoregulatory effects on T and
B cell growth and functions,s< PAF enhances the
DNA synthesis in guinea-pig bone marrow cells
2
and has been detected in human thymus.
3 Although
data have suggested immune regulation by PAF
in vitro, the absence of assessment of PAF in
haematopoietic organs may cast some doubts about
the reality of its putative physiological role in vivo.
Thus the authors have examined PAF levels and
acetylhydrolase activity in haematopoietic organs of
rats before and after depletion of haematopoietic
proliferative cells with 5-fluoro-uracil (5-FU), a
potent chemotherapeutic drug with apoptotic
ei:fects.4
Materials and Methods
Animals: Normal adult female Wistar rats weighing
300-400 g were housed in two groups of five. One
group was given an intraperitoneal injection of
5-FU (200 mg/kg). Sixty hours later all the animals
were killed by cervical dislocation.
Processing of samples for PAF determinations: Half the
thymus, half the spleen, and a part of the liver were
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weighed, minced into small pieces, washed in saline,
and homogenized in 4 ml of ethanol. One ml of
blood was mixed with 4 ml of ethanol. The bone
marrow was flushed from a femur with 2 ml of
ethanol. Lipids from all samples were extracted with
ethanol for 10 h at 4C. Phospholipids were purified
by thin layer chromatography (TLC).
15 Areas of
samples on TLC plates with RF values correspond-
ing to a PAF synthetic standard were extracted, and
assayed for PAF activity.
Processing of samples for acetylhydrolase measurements: Half
the thymus, half the spleen, and a part of the liver
were weighed, minced into small pieces, washed in
saline, and homogenized in 2 ml of Tyrode’s buffer
at 4C. Serum samples were recovered from blood.
The bone marrow was. flushed from a femur with
2 ml of Tyrode’s buffer. Samples were centrifuged
and supernatants were stored at -80C until assay
of the PAF acetylhydrolase activity.
PAF assay: Washed rabbit platelets were prepared
as described previously.
6 Aspirin-treated platelets
in Tyrode’s buffer containing the adenosine dipho-
sphate scavenger mixture, creatine phosphate
(lmM)/creatine phosphokinase (10U/ml) were
stirred in an aggregometer (Labintec, France).
Aggregating activity of the samples was measured
using a calibration curve obtained with 2.5 to 50 pg
synthetic PAF (Novabiochem, Switzerland).
PAF acetylhydrolase assay: For the assay, supernatants
were tested essentially as described previously.3’16
Results were expressed in nM of PAF degraded per
rain per g (wet weight) of femur, or ml of serum,
as means of duplicate determinations. The variation
between duplicates was less than 3%.
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Statistical analysis: Data are shown as mean -+- S.E.M.
of five animals. Normality of data distribution was
assessed using the Kolmogorov Smirnov’s test.
Means were compared using Student’s t-test for
paired variables. A p<0.05 was considered
significant.
Table 1. Acetylhydrolase activity in spleen, thymus, liver,
femoral bone marrow and serum on control and 5-FU treated
rats
Acetyl hydrolase activity
After 5- FU
Organ Controls treatment p
Results
Lipids were extracted from the spleen, thymus,
liver, blood and femoral bone marrow. After
purification by TLC, PAF was assessed by platelet
aggregation. As shown in Fig. 1, PAF was found
in spleen, thymus and liver. PAF was detected in
bone marrow (0.25 +__ 0.04 ng PAF/femur). Minute
amounts of PAF were assessed in blood (0.02
0.01 ng PAF/ml). In control rats PAF levels per g
(wet weight) were six-fold and two-fold greater in
spleen and thymus than in liver (p--0.03). In
controls acetylhydrolase activity is significantly
higher in spleen than in liver and thymus (p 0.008
and p- 0.002, respectively), and in liver than in
thymus (p 0.001) (Table 1). A weak acetylhydro-
lase activity was docmented in bone marrow. The
enzyme activity in blood was similar to that given
17 in a previous report.
Acetylhydrolase activities were not significantly
different in rats with or without 5-FU (Table 1).
After 5-FU, elevated levels of PAF per g (wet
weight) were documented in thymus and spleen
(p > 0.05) but not in liver (p > 0.1) (Fig. 1). PAF
amounts in blood (0.04-k 0.02 ng PAF/ml and in
bone marrow (0.13 _+ 0.01 ng PAF/femur) were not
significantly different when compared with control
values (p > 0.1).
20-
10
p < 0.05
p < 0.05
ns
Spleen Thymus Liver
FIG. 1. PAF levels in spleen, thymus and liver of control and 5-FU-treated
rats. PAF was expressed as ng PAF per g of wet weight. Mean -I- S.E.M.
of five animals, ns" no significant difference.
Thymus 33.8 _+ 3.0 57.6 _+ 12.1 0.06
Spleen 148.2 _+ 19.9 174.0 _+ 21.6 0.25
Liver 73.0 _+ 1.1 80.0 +_ 6.1 0.12
Bone marrow* 3.9 _+ 0.3 4.3 ___
0.4 0.3
Serum** 97.8 _+ 13.5 66.47 ___
8.9 0.09
Acetylhydrolase was expressed as nmol PAF degraded per min
per g of wet weight. *in nmol PAF per min per femur; **in nmol
PAF per min per ml serum. Mean S.E.M. of five animals.
Treatment with 5-FU significantly decreased the
weight of the spleen (0.58 g +__ 0.02 vs. 1.04 g +__ 0.08,
p < 0.003) but not of the thymus (0.48 g -+- 0.1 vs.
0.54 g __+ 0.08, p 0.13). As previously shown this
decrease is due to the disappearance of cycling cells
killed by 5-FU treatment.
18
Chemical characterization of PAF was based on
several criteria including its TLC behaviour
analogous to that of authentic PAF; the loss of its
biological activity after treatment by phospholipase
A2 but not by lipase A1 from Rhizopus arrhizus; and
the inhibition of the platelet aggregation induced
by organ-extracted PAF with the PAF antagonist
CV 3988 (Takeda Chemical Ind., Osaka, Japan)
(data not shown).
Discussion
Numerous studies have reported the immuno-
regulatory functions of PAF in vitro, s-ll However,
the absence of data reporting the presence of PAF
in haematopoietic organs may cast some doubts
about its putative role in vivo. The authors
documented PAF in bone marrow, spleen and
thymus of rats, strengthening the hypothesis that
PAF could play a role in the modulation of the
immune response in vivo. Because only minute
amounts of PAF are detected in blood, the PAF
documented in spleen and thymus is probably
linked to a local PAF production. PAF is also
present in bone marrow (0.25 ng PAF per femur)
suggesting that PAF could interfere with the
process leading to haematopoiesis. Kato et al.12 have
reported that 55 to 550 pg of a non-metabolizable
PAF agonist enhanced the DNA synthesis in
guinea-pig bone marrow cells, indicating that the
levels of PAF that were detected in femoral bone
marrow could be of a physiological significance.
Clearly the presence ofPAF in human bone marrow
deserves to be investigated.
After 5-FU treatment similar levels of PAF were
noted in blood, liver and femoral bone marrow. In
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contrast, elevated levels of PAF were documented
in spleen and thymus. Because 5-FU is known to
affect cells in proliferation,
18 the present data
suggest that PAF in spleen and thymus may
originate from non-lymphoid populations such as
macrophages, epithelial cells, and/or dendritic cells
rather than B or T cells. Similarly in bone marrow
PAF may originate from stromal cells which are the
major component of the haemopoietic micro-
environment rather than progenitor cells. The
hypothesis of a PAF production from non-
lymphoid populations in thymus has been sug-
gested by Salem et al.,
13 who reported that CD2
negative cells in the human thymus were far more
efficient than CD2 positive ceils (i.e. thymocytes) in
producing PAF. Furthermore even though PAF
production has been reported from human
lymphoid leukaemic cells19’2 and from a human
CD4+ T lymphocyte clone,
21 the release of PAF
from normal human lymphocytes has been
unsuccessful.22’23 At present it is unclear whether
the absence of data showing PAF production from
haematopoietic precursor cells is due to a paucity
of studies, or to the fact that negative results have
not been published. Strengthening the putative role
of PAF on these immature cells, Saito et a.24 have
reported that PAF induced eosinophilic and
basophilic differentiation in human haematopoietic
precursor cells.
Because acetylhydrolase activity in thymus and
spleen did not significantly vary after 5-FU
treatment, the elevated amounts of PAF docu-
mented in thymus and spleen seem related to an
enhanced PAF production. The molecular signal(s)
and the cell type(s) implicated in PAF production
in thymus and spleen are currently unknown.
Anticancer drugs such as 5-FU have been reported
to induce apoptosis in cancer cells and in
thymocytes.
14 Thus, regardless of the origin ofPAF
in thymus, its function could be of importance since
data have shown that, in association with another
signal, PAF could modulate apoptotic processes in
an immature T-cell line.
is
It is still difficult to evaluate the physiological
role of PAF in vivo in haematopoietic organs such
as bone marrow, spleen and thymus. However, its
presence strengthens the in vitro data which show
that PAF may participate in the mechanism of
programmed cell death and is a modulator of
cellular immune responses.
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